MARAVIROC

Maraviroc, a synthetic HIV-1 entry inhibitor, selectively and reversibly antagonises CC chemokine receptor-5 (CCR5) coreceptors found on human CD4+ cells. This prevents interaction of HIV-1 glycoprotein 120 (gp120) and CCR5 necessary for CCR5-tropic HIV-1 to enter cells.

Maraviroc is used in the treatment of HIV-1 infection.

Avoid Maraviroc use in patients with the following conditions:

  • Hypersensitivity
  • Lactation
  • Concomitant use with potent CYP3A enzyme inhibitors and inducers in patients with severe (CrCl <30 mL/min) kidney impairment

Maraviroc may bring about the following side effects:

  • Significant: Postural hypotension, immune reconstitution syndrome, increased risk of infection and malignancy, osteonecrosis, MI, myocardial ischaemia.
  • Nervous: Asthenia, dizziness, headache, somnolence, insomnia, depression, malaise, paraesthesia, dysaesthesia, seizures.
  • GI: Abdominal pain and distention, constipation, diarrhoea, dyspepsia, nausea, vomiting, anorexia, flatulence.
  • Resp: Cough, upper resp tract infection.
  • Hepatic: Cirrhosis.
  • Genitourinary: Renal failure, proteinuria, bladder problems.
  • Haematologic: Neutropenia, bone marrow depression.
  • Musculoskeletal: Muscle spasm, back pain, myositis, rhabdomyolysis, increased creatine kinase.
  • Dermatologic: Pruritus.
  • Potentially Fatal: Hepatotoxicity and hepatic failure with hypersensitivity reactions [e.g. severe rash, fever, increased IgE, eosinophilia, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS)].

Precautions

Take precautions in people with the following conditions:

  • Patient with severe heart disease
  • History of postural hypotension
  • Liver (e.g. chronic active hepatitis B or C) and kidney impairment
  • Pregnancy
  • Patients taking potent CYP3A enzyme inhibitors (with or without potent inducers) or potent CYP3A enzyme inducers (without potent inhibitors)

This drug is not indicated for use in patients with CXCR4- or dual/mixed tropic HIV-1 infection

 

Interactions

Maraviroc may interact with the following medicines:

  • CYP3A enzyme inhibitors (e.g. protease inhibitors except ritonavir-boosted tipranavir, delavirdine, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, boceprevir)
  • CYP3A enzyme inducers (e.g. efavirenz, etravirine, rifampicin, carbamazepine, phenobarbital, phenytoin)
  • Medications that lower blood pressure

Overdose may lead to postural hypotension. In this case, supportive treatment should be done including keeping the patient in supine position. Assess vital signs, BP, and ECG. Employ gastric lavage/activated charcoal, or induce emesis to remove unabsorbed drug.

 

Available Brand:

  • Selzentry

Related Articles

ZADAXIN

Zadaxin is a synthetic 28-amino acid peptide with numerous biological properties that are mostly focused on enhancing the immune response. [...]

YEASTAZOL

Yeastazol is an imidazole derivative used topically as an antifungal drug. This drug works by inhibiting the formation of ergosterol, [...]

XAMBREX

Xambrex's active ingredient, Xambrex hydrochloride, has been shown to increase secretions from the respiratory tract. It makes more surfactant in [...]